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Abstract 
This themed issue provides up-to-date review and research articles covering the theranostic 
applications in the combined fields of protease research, diagnostics and drug development. 
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Proteases, which are also known as proteolytic 
enzymes, are important signaling proteins that play 
crucial roles in a number of pathological processes, 
such  as  cancer,  inflammatory  and  cardiovascular 
diseases  and  neurological  disorders  [1].  Proteases 
were previously considered enzymes that only cata-
lyze  protein  degradation  by  hydrolysis  of  peptide 
bonds. Nowadays, proteases are recognized as excep-
tionally important molecules that are engaged in nu-
merous vital life processes. Because certain states of 
protease activity can affect, lead to or signal specific 
diseases, it is not surprising that proteases have been 
actively  investigated  as  potential  therapeutic  and 
imaging targets. For instance, various novel protease 
inhibitors and protease-targeted prodrugs are under 
active clinical investigations and some of which are 
expected  to  enter  the  market  in  the  next  few  years 
[2-4]. Since certain types of proteases can be used as 
biomarkers  and/or  prognostic  markers,  different 
types  of  diagnostics  measuring  proteases’  activities 
have been widely developed [5]. In addition, recent 
technological  developments  in  molecular  imaging 
have allowed detecting and imaging protease activi-
ties in living organisms using different imaging mo-
dalities.  In  this  special  issue  of  Theranostics,  we 
would like to share ideas and opinions on why pro-
tease-targeted imaging and therapy is attractive in the 
drug  development  and  diagnosis  field  through 
up-to-date review and research articles.  
This  special  issue  contains  10  review  and  re-
search articles. The paper by Kim and Kim [6] pre-
sents  the  design  of  quantum  dot-based  molecular 
probes that can sense protease activities via fluores-
cence and bioluminescence resonance energy transfer 
systems.    These  promising  protease  sensors  are  ex-
pected to identify and contribute to the understanding 
of the specific role of proteases in particular biological 
processes and have great potential as high throughput 
drug screening tools for screening novel protease in-
hibitors  as  therapeutic  drugs.  In  nature,  proteolytic 
degradation often induces or sensitizes the controlled 
self-assemblies of certain proteins. Inspired by these 
unique  phenomena,  various  self-assembled  supra-
molecular nanostructures built up by enzymatic pro-
cesses have been studied. The exciting article by Chen 
and Liang [7] focuses on the concept and application 
of these enzyme-catalyzed or –regulated  nanostruc-
tures for theranostics. In another review article, Chen 
et  al.  [8]  introduces  how  molecular  imaging  tech-
niques can contribute to understanding the signaling 
cascades involved in cell death by targeting important 
kinases and proteases. The paper by Choi et al.  [5] 
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introduces  protease-targeted  sensing  and  imaging 
applications, focuses on the strategies to develop so-
phisticated  protease-sensitive  prodrugs  targeting 
various  diseases  and  elucidates  the  importance  of 
their therapeutic applications in the field of drug de-
velopment.  
A  number  of  research  articles  introduce  new 
theranostic  materials  or  systems  targeting  specific 
proteases in vivo, in cells and in clinical samples. Yhee 
et  al.  [9]  report  fluorogenic  peptides  targeting  two 
popular  proteases,  cathepsin  B  and  matrix  metallo-
proteinases (MMPs), and their applications in cancer 
theranostics. Jang and Choi [10] show a similar sub-
strate  using  an  MMP  fluorogenic  peptide  that  can 
successfully  turn  into  an  theranostic  agent  when 
combined  with  photodynamic  agents  and  gold  na-
norods.  They  demonstrate  both  imaging  and  thera-
peutic  applicability  of  this  MMP-activatable  photo-
sensitizing system in cellular models. Clinical transla-
tion of in vitro MMP diagnostics was also reported. 
Ryu et al. [11] exhibit an MMP diagnostic kit designed 
by immobilization of polymer-MMP probe conjugates 
and exemplify its use in monitoring early stages of 
osteoarthritis  and  acute  inflammatory  conditions  of 
the  knee  joint  by  measuring  MMP  activities  in  the 
synovial  fluids  from  patients.  Two  papers  [12,  13] 
describe methods of real-time monitoring of apoptosis 
in  vivo  and  in  cells  by  imaging  the  activity  of  the 
apoptotic  protease,  caspase-3,  using  bioluminescent 
and fluorescent proteins that are sensitive to caspa-
se-3. Since the most effective anticancer therapeutics 
rely  on  apoptosis,  developing  new  techniques  that 
enable real-time imaging of apoptotic processes will 
improve the understanding of drug-induced apopto-
sis  and  assist  in  the  screening  of  apoptosis-related 
novel drug candidates. Lastly, the exciting paper by 
Habibollahi et al. [14] report a highly clinically trans-
latable  technique  by  demonstrating  how  imaging 
protease  biomarkers  can  improves  the  detection  of 
esophageal adenocarcinoma in orthotopic small ani-
mal models when combined with a dual-channel flu-
orescent endoscopic system.   
The  field  of  protease  research  is  far-reaching 
ranging  fundamental  biology  to  drug  development 
and to molecular imaging. Currently, one of the hot 
topics of research is the identification and validation 
of target proteases for drug development and diag-
nosis. Understanding the complex protease signaling 
in various disease conditions should be established to 
make these unique molecules useful in our lives. For 
successful  real  applications,  multidisciplinary  re-
search, like the combination of biological knowledge, 
engineering technologies, and clinical tools, is needed. 
Although  a  few  examples  were  provided  in  this 
themed issue, there is no doubt that theranostics will 
play  the  role  of  locomotive,  translating  prote-
ase-related applications into the clinic. We thank all 
the authors for contributing their papers and hope the 
topics covered in this issue will provide new infor-
mation to readers of Theranostics. 
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